Table 1 Summary of baseline characteristics (Chinese ITT population)
Pazopanib | Sunitinib | Total | P value | |
|---|---|---|---|---|
Number of patients | 109 | 100 | 209 | |
Age, (years) | 0.8991 | |||
Mean (SD) | 55.5 (11.57) | 55.7 (11.16) | 55.6 (11.35) | |
Median (min, max) | 58 (18, 76) | 57 (23, 79) | 57 (18, 79) | |
Sex, n (%) | 0.5611 | |||
Female | 30 (28) | 24 (24) | 54 (26) | |
Male | 79 (72) | 76 (76) | 155 (74) | |
Weight (kg), n (%) | 0.7388 | |||
Mean (SD) | 66.44 (12.665) | 67.02 (12.414) | 66.72 (12.519) | |
Median (min, max) | 67 (36, 110) | 66 (40, 95) | 67 (36, 110) | |
Primary tumor type, n (%) | NA | |||
Renal cell | 109 (100) | 100 (100) | 209 (100) | |
Histology, n (%) | 0.4290 | |||
Clear cell | 107 (98) | 96 (96) | 203 (97) | |
Predominantly clear cell | 2 (2) | 4 (4) | 6 (3) | |
Stage at screening, n (%) | 0.9151 | |||
I | 1 (< 1) | 0 | 1 (< 1) | |
II | 0 | 1 (1) | 1 (< 1) | |
III | 3 (3) | 3 (3) | 6 (3) | |
IV | 104 (95) | 96 (96) | 200 (96) | |
Missing | 1 (< 1) | 0 | 1 (< 1) | |
Metastatic disease at screening, n (%) | 0.3023 | |||
Yes | 106 (97) | 97 (97) | 203 (97) | |
No | 2 (2) | 3 (3) | 5 (2) | |
Missing | 1 (< 1) | 0 | 1 (< 1) | |
MSKCC risk category, n (%) | 0.1588 | |||
Favorable risk | 26 (24) | 34 (34) | 60 (29) | |
Intermediate risk | 75 (69) | 64 (64) | 139 (67) | |
Poor risk | 6 (6) | 2 (2) | 8 (4) | |
Unknown | 2 (2) | 0 | 2 (<1) | |
Heng risk category, n (%) | 0.2168 | |||
Favorable risk | 24 (22) | 33 (33) | 57 (27) | |
Intermediate risk | 70 (64) | 55 (55) | 125 (60) | |
Poor risk | 14 (13) | 12 (12) | 26 (12) | |
Unknown | 1 (< 1) | 0 | 1 (< 1) | |